Unknown

Dataset Information

0

Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

ABSTRACT: Roughly a third of the world's population is estimated to have latent Mycobacterium tuberculosis infection, being at risk of developing active tuberculosis (TB) during their lifetime. Given the inefficacy of prophylactic measures and the increase of drug-resistant M. tuberculosis strains, there is a clear and urgent need for the development of new and more efficient chemotherapeutic agents, with selective toxicity, to be implemented on patient treatment. The component enzymes of the shikimate pathway, which is essential in mycobacteria and absent in humans, stand as attractive and potential targets for the development of new drugs to treat TB. This review gives an update on published work on the enzymes of the shikimate pathway and some insight on what can be potentially explored towards selective drug development.

SUBMITTER: Nunes JES 

PROVIDER: S-EPMC7144000 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

<i>Mycobacterium tuberculosis</i> Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

Nunes José E S JES   Duque Mario A MA   de Freitas Talita F TF   Galina Luiza L   Timmers Luis F S M LFSM   Bizarro Cristiano V CV   Machado Pablo P   Basso Luiz A LA   Ducati Rodrigo G RG  

Molecules (Basel, Switzerland) 20200311 6

Roughly a third of the world's population is estimated to have latent <i>Mycobacterium tuberculosis</i> infection, being at risk of developing active tuberculosis (TB) during their lifetime. Given the inefficacy of prophylactic measures and the increase of drug-resistant <i>M. tuberculosis</i> strains, there is a clear and urgent need for the development of new and more efficient chemotherapeutic agents, with selective toxicity, to be implemented on patient treatment. The component enzymes of th  ...[more]

Similar Datasets

Unknown Potent inhibitors of a shikimate pathway enzyme from Mycobacterium tuberculosis: combining mechanism- and modeling-based design.
| S-EPMC3093739 | biostudies-literature
Unknown Adenylating enzymes in Mycobacterium tuberculosis as drug targets.
| S-EPMC3808994 | biostudies-literature
Unknown Mycobacterium tuberculosis ?-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs.
| S-EPMC6834203 | biostudies-literature
Unknown Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials.
| S-EPMC4362912 | biostudies-literature
Transcriptomics Transcriptional Response of Mycobacterium tuberculosis H37Rv to Anti-TB drugs
2018-09-07 | GSE119585 | GEO
Unknown Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
| S-EPMC5410965 | biostudies-literature
Unknown Combined Bioinformatic and Rational Design Approach To Develop Antimicrobial Peptides against Mycobacterium tuberculosis.
| S-EPMC4862459 | biostudies-literature
Unknown Identification of Missing Carbon Fixation Enzymes as Potential Drug Targets in Mycobacterium Tuberculosis.
| S-EPMC6340126 | biostudies-literature
Unknown Effects of the magnesium and chloride ions and shikimate on the structure of shikimate kinase from Mycobacterium tuberculosis.
| S-EPMC2330112 | biostudies-literature
Unknown The conserved Lysine69 residue plays a catalytic role in Mycobacterium tuberculosis shikimate dehydrogenase.
| S-EPMC2789096 | biostudies-literature